Acumen Pharmaceuticals, Inc. (ABOS)
$
1.02
Key metrics
Financial statements
Free cash flow per share
-1.6945
Market cap
63 Million
Price to sales ratio
0
Debt to equity
0.1865
Current ratio
8.0221
Income quality
0.8815
Average inventory
0
ROE
-0.5824
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing therapies for Alzheimer's disease, has a weighted average number of shares outstanding at 60,013,277.00 highlighting the company's shareholder base. The company reported a net loss of -$102,329,000.00 indicating challenges in its operations as it navigates the complexities of drug development. The gross profit ratio stands at 0.00 reflecting the efficiency of the company's production and sales operations, despite the inherent risks in the biopharmaceutical landscape. Additionally, Acumen incurred an interest expense of $4,068,000.00 which underscores its debt servicing obligations while pursuing innovation in therapeutic solutions. The company achieved a revenue of $0.00 indicating its niche market focus and commitment to addressing unmet needs in the treatment of Alzheimer's disease through its targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody currently in Phase I clinical trials targeting soluble amyloid-beta oligomers. In the financial market, the stock is affordable at $1.02 making it suitable for budget-conscious investors seeking entry points into emerging biopharmaceutical opportunities. However, the stock has a low average trading volume of 222,639.00 indicating lower market activity that may influence liquidity for potential investors. With a market capitalization of $61,784,868.00 the company is classified as a small-cap player, which often involves higher volatility but also the potential for substantial growth. Acumen Pharmaceuticals is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and advancing the development of new therapies. Furthermore, it belongs to the Healthcare sector, driving innovation and growth as it undertakes its mission to enhance the lives of individuals affected by Alzheimer's disease through its promising research and development initiatives.
Is Acumen Pharmaceuticals, Inc. (ABOS) a good investment?
Investing in Acumen Pharmaceuticals, Inc. (ABOS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Acumen Pharmaceuticals, Inc. (ABOS)'s stock forecast?
Analysts predict Acumen Pharmaceuticals, Inc. stock to fluctuate between $0.86 (low) and $3.60 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Acumen Pharmaceuticals, Inc.'s market capitalization?
As of 2025-05-28, Acumen Pharmaceuticals, Inc.'s market cap is $61,784,868, based on 60,573,400 outstanding shares.
How does Acumen Pharmaceuticals, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Acumen Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Acumen Pharmaceuticals, Inc. (ABOS) stock?
To buy Acumen Pharmaceuticals, Inc. (ABOS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABOS. Place an order (Market, Limit, etc.).
What is the best time to invest in Acumen Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Acumen Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.71 | Growth: 58.33%.
Where can I find Acumen Pharmaceuticals, Inc.'s investor relations reports?
Visit https://acumenpharm.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Acumen Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Acumen Pharmaceuticals, Inc. stock?
All-time high: $26.98 (2021-07-01) | All-time low: $0.86 (2025-04-21).
What are the key trends affecting Acumen Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
16 days ago
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and CBO Dr. Jim Doherty - President and CDO Dr. Eric Siemers - Chief Medical Officer Conference Call Participants Sarah Medeiros - Cantor Fitzgerald Tom Shrader - BTIG Ting Liu - UBS Operator Good day and thank you for standing by. Welcome to the Acumen Pharmaceuticals Q1 2025 Conference Call and Webcast.
globenewswire.com
22 days ago
NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET.
globenewswire.com
23 days ago
NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2025 financial results on Tuesday, May 13, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
globenewswire.com
2 months ago
Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease
seekingalpha.com
2 months ago
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and Chief Business Officer Jim Doherty - President and Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - Bank of America Pete Stavropoulos - Cantor Fitzgerald Ting Liu - UBS Tom Shrader - BTIG Ananda Ghosh - H. C. Wainwright & Company Operator Good day and welcome to Acumen Pharma Fiscal Year 2024 Conference Call and Webcast.
globenewswire.com
2 months ago
NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
globenewswire.com
2 months ago
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today's Marketplace host Elizabeth Hart to discuss Alzheimer's Disease.
globenewswire.com
3 months ago
Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug
globenewswire.com
3 months ago
NEWTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in webcast fireside chats at two upcoming investor conferences:
globenewswire.com
6 months ago
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
See all news
